The non-alcoholic steatohepatitis (NASH) drug-development race poses many variables, including which endpoint to pursue in pivotal studies. Gilead Sciences Inc. confirmed how challenging this can be by choosing to demonstrate a fibrosis benefit in very sick patients with its candidate selonsertib, which failed by this measure in a Phase III clinical trial.
What this means for the company's future chances in NASH and for other firms in the space remains unclear, but optimism for other approaches may have waned based on data from selonsertib in STELLAR-4 – the first Phase III study with results in NASH patients
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?